Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Cassano

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
ESMO Open|August 30, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trialE Martinelli, C Cardone, T Troiani, et al.
Journal of Cellular Physiology|December 12, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experienceLaura Pizzuti, Antonio Giordano, Andrea Michelotti, et al.
Journal of Cellular Physiology|January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidenceEriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Frontiers in Oncology|June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational studyFrancesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
International Journal of Cancer|July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
ESMO Open|August 30, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trialE Martinelli, C Cardone, T Troiani, et al.
Journal of Cellular Physiology|December 12, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experienceLaura Pizzuti, Antonio Giordano, Andrea Michelotti, et al.
Journal of Cellular Physiology|January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidenceEriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Frontiers in Oncology|June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational studyFrancesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
International Journal of Cancer|July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Pageof 10